Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Genetic aberrations in iPSCs are introduced by a transient G1/S cell cycle checkpoint deficiency.

Araki R, Hoki Y, Suga T, Obara C, Sunayama M, Imadome K, Fujita M, Kamimura S, Nakamura M, Wakayama S, Nagy A, Wakayama T, Abe M.

Nat Commun. 2020 Jan 10;11(1):197. doi: 10.1038/s41467-019-13830-x.

2.

Defects in dosage compensation impact global gene regulation in the mouse trophoblast.

Sakata Y, Nagao K, Hoki Y, Sasaki H, Obuse C, Sado T.

Development. 2017 Aug 1;144(15):2784-2797. doi: 10.1242/dev.149138. Epub 2017 Jul 6.

3.

Low- and High-LET Ionizing Radiation Induces Delayed Homologous Recombination that Persists for Two Weeks before Resolving.

Allen CP, Hirakawa H, Nakajima NI, Moore S, Nie J, Sharma N, Sugiura M, Hoki Y, Araki R, Abe M, Okayasu R, Fujimori A, Nickoloff JA.

Radiat Res. 2017 Jul;188(1):82-93. doi: 10.1667/RR14748.1. Epub 2017 May 23.

4.

The Number of Point Mutations in Induced Pluripotent Stem Cells and Nuclear Transfer Embryonic Stem Cells Depends on the Method and Somatic Cell Type Used for Their Generation.

Araki R, Mizutani E, Hoki Y, Sunayama M, Wakayama S, Nagatomo H, Kasama Y, Nakamura M, Wakayama T, Abe M.

Stem Cells. 2017 May;35(5):1189-1196. doi: 10.1002/stem.2601. Epub 2017 Mar 27.

5.

Do Carpets Alleviate Stress?

Hoki Y, Sato K, Kasai Y.

Iran J Public Health. 2016 Jun;45(6):715-20.

6.

A new Xist allele driven by a constitutively active promoter is dominated by Xist locus environment and exhibits the parent-of-origin effects.

Amakawa Y, Sakata Y, Hoki Y, Arata S, Shioda S, Fukagawa T, Sasaki H, Sado T.

Development. 2015 Dec 15;142(24):4299-308. doi: 10.1242/dev.128819. Epub 2015 Oct 28.

7.

Induced pluripotent stem cell generation-associated point mutations arise during the initial stages of the conversion of these cells.

Sugiura M, Kasama Y, Araki R, Hoki Y, Sunayama M, Uda M, Nakamura M, Ando S, Abe M.

Stem Cell Reports. 2014 Jan 2;2(1):52-63. doi: 10.1016/j.stemcr.2013.11.006. eCollection 2014 Jan 14.

8.

The CENP-O complex requirement varies among different cell types.

Kagawa N, Hori T, Hoki Y, Hosoya O, Tsutsui K, Saga Y, Sado T, Fukagawa T.

Chromosome Res. 2014 Sep;22(3):293-303. doi: 10.1007/s10577-014-9404-1. Epub 2014 Jan 31.

9.

Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.

Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiura M, Ideno H, Shimada A, Nifuji A, Abe M.

Nature. 2013 Feb 7;494(7435):100-4. doi: 10.1038/nature11807. Epub 2013 Jan 9.

PMID:
23302801
10.

Targeted gene silencing in mouse germ cells by insertion of a homologous DNA into a piRNA generating locus.

Yamamoto Y, Watanabe T, Hoki Y, Shirane K, Li Y, Ichiiyanagi K, Kuramochi-Miyagawa S, Toyoda A, Fujiyama A, Oginuma M, Suzuki H, Sado T, Nakano T, Sasaki H.

Genome Res. 2013 Feb;23(2):292-9. doi: 10.1101/gr.137224.112. Epub 2012 Nov 6.

11.

Crucial role of c-Myc in the generation of induced pluripotent stem cells.

Araki R, Hoki Y, Uda M, Nakamura M, Jincho Y, Tamura C, Sunayama M, Ando S, Sugiura M, Yoshida MA, Kasama Y, Abe M.

Stem Cells. 2011 Sep;29(9):1362-70. doi: 10.1002/stem.685.

12.

Incomplete X-inactivation initiated by a hypomorphic Xist allele in the mouse.

Hoki Y, Ikeda R, Mise N, Sakata Y, Ohhata T, Sasaki H, Abe K, Sado T.

Development. 2011 Jul;138(13):2649-59. doi: 10.1242/dev.061226. Epub 2011 May 25.

13.

Role for piRNAs and noncoding RNA in de novo DNA methylation of the imprinted mouse Rasgrf1 locus.

Watanabe T, Tomizawa S, Mitsuya K, Totoki Y, Yamamoto Y, Kuramochi-Miyagawa S, Iida N, Hoki Y, Murphy PJ, Toyoda A, Gotoh K, Hiura H, Arima T, Fujiyama A, Sado T, Shibata T, Nakano T, Lin H, Ichiyanagi K, Soloway PD, Sasaki H.

Science. 2011 May 13;332(6031):848-52. doi: 10.1126/science.1203919.

14.

MITOPLD is a mitochondrial protein essential for nuage formation and piRNA biogenesis in the mouse germline.

Watanabe T, Chuma S, Yamamoto Y, Kuramochi-Miyagawa S, Totoki Y, Toyoda A, Hoki Y, Fujiyama A, Shibata T, Sado T, Noce T, Nakano T, Nakatsuji N, Lin H, Sasaki H.

Dev Cell. 2011 Mar 15;20(3):364-75. doi: 10.1016/j.devcel.2011.01.005.

15.

Generation of genome integration-free induced pluripotent stem cells from fibroblasts of C57BL/6 mice without c-Myc transduction.

Jincho Y, Araki R, Hoki Y, Tamura C, Nakamura M, Ando S, Kasama Y, Abe M.

J Biol Chem. 2010 Aug 20;285(34):26384-9. doi: 10.1074/jbc.M110.115915. Epub 2010 Jun 16.

16.

Conversion of ancestral fibroblasts to induced pluripotent stem cells.

Araki R, Jincho Y, Hoki Y, Nakamura M, Tamura C, Ando S, Kasama Y, Abe M.

Stem Cells. 2010 Feb;28(2):213-20. doi: 10.1002/stem.282.

17.

A proximal conserved repeat in the Xist gene is essential as a genomic element for X-inactivation in mouse.

Hoki Y, Kimura N, Kanbayashi M, Amakawa Y, Ohhata T, Sasaki H, Sado T.

Development. 2009 Jan;136(1):139-46. doi: 10.1242/dev.026427. Epub 2008 Nov 26.

18.

Crucial role of antisense transcription across the Xist promoter in Tsix-mediated Xist chromatin modification.

Ohhata T, Hoki Y, Sasaki H, Sado T.

Development. 2008 Jan;135(2):227-35. Epub 2007 Dec 5.

19.

Pathomechanism of entrapment neuropathy in diabetic and nondiabetic rats reared in wire cages.

Nishimura T, Hirata H, Tsujii M, Iida R, Hoki Y, Iino T, Ogawa S, Uchida A.

Histol Histopathol. 2008 Feb;23(2):157-66. doi: 10.14670/HH-23.157.

PMID:
17999372
20.

8-Nitroguanine as a potential biomarker for progression of malignant fibrous histiocytoma, a model of inflammation-related cancer.

Hoki Y, Murata M, Hiraku Y, Ma N, Matsumine A, Uchida A, Kawanishi S.

Oncol Rep. 2007 Nov;18(5):1165-9.

PMID:
17914567
21.

Intra-osseous ganglion of the proximal humerus: a case report.

Nishimura T, Tsujii M, Kusuzaki K, Hoki Y, Uchida A, Hirata H.

J Orthop Surg (Hong Kong). 2007 Apr;15(1):102-5. Review.

PMID:
17429129
22.

iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis.

Hoki Y, Hiraku Y, Ma N, Murata M, Matsumine A, Nagahama M, Shintani K, Uchida A, Kawanishi S.

Cancer Sci. 2007 Feb;98(2):163-8. Erratum in: Cancer Sci. 2007 Mar;98(3):464.

23.

Tsix defective in splicing is competent to establish Xist silencing.

Sado T, Hoki Y, Sasaki H.

Development. 2006 Dec;133(24):4925-31. Epub 2006 Nov 15.

24.

Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas.

Shintani K, Matsumine A, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Hoki Y, Uchida A.

Virchows Arch. 2006 Dec;449(6):673-81. Epub 2006 Nov 14.

PMID:
17103226
25.
26.

Tsix silences Xist through modification of chromatin structure.

Sado T, Hoki Y, Sasaki H.

Dev Cell. 2005 Jul;9(1):159-65.

27.

Effect of Atm disruption on spontaneously arising and radiation-induced deletion mutations in mouse liver.

Furuno-Fukushi I, Masumura K, Furuse T, Noda Y, Takahagi M, Saito T, Hoki Y, Suzuki H, Wynshaw-Boris A, Nohmi T, Tatsumi K.

Radiat Res. 2003 Nov;160(5):549-58.

PMID:
14565827
28.

Growth retardation and skin abnormalities of the Recql4-deficient mouse.

Hoki Y, Araki R, Fujimori A, Ohhata T, Koseki H, Fukumura R, Nakamura M, Takahashi H, Noda Y, Kito S, Abe M.

Hum Mol Genet. 2003 Sep 15;12(18):2293-9. Epub 2003 Jul 29.

PMID:
12915449
29.
30.

Enhanced phosphorylation of p53 serine 18 following DNA damage in DNA-dependent protein kinase catalytic subunit-deficient cells.

Araki R, Fukumura R, Fujimori A, Taya Y, Shiloh Y, Kurimasa A, Burma S, Li GC, Chen DJ, Sato K, Hoki Y, Tatsumi K, Abe M.

Cancer Res. 1999 Aug 1;59(15):3543-6.

31.

Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.

Hoki Y, Fujimori A, Pommier Y.

Cancer Chemother Pharmacol. 1997;40(5):433-8.

PMID:
9272121
32.
33.

Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.

Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y.

Cancer Res. 1996 Oct 1;56(19):4430-7.

34.
35.

Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.

Gupta M, Abdel-Megeed M, Hoki Y, Kohlhagen G, Paull K, Pommier Y.

Mol Pharmacol. 1995 Oct;48(4):658-65.

PMID:
7476891
36.

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y.

Cancer Res. 1995 Mar 15;55(6):1339-46.

Supplemental Content

Support Center